Pharmaceutical - Bayer

Filter

Current filters:

Bayer

Popular Filters

1 to 25 of 290 results

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Highlights of EMA Pharmacovigilance unit meeting

09-11-2014

At its meeting last week, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

BayerBiogen IdecCSL BehringEuropeHelixateHematologyKogenateNeurologicalPharmaceuticalRegulationTecfidera

Bayer sees strong third-qtr sales and earnings growth

Bayer sees strong third-qtr sales and earnings growth

30-10-2014

Reporting third-quarter 2014 financials this morning, German pharma major Bayer (BAYN: DE) said group…

BayerFinancialPharmaceutical

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

09-10-2014

The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for the…

BayerNeurologicalPharmaceuticalRegulationSativexUK

Bayer’s Jadelle to be listed in New Zealand

Bayer’s Jadelle to be listed in New Zealand

26-09-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

BayerJadelleMarkets & MarketingNew ZealandPharmaceuticalPricingReproductiveWomen's Health

Bayer’s Eylea approved in Japan for myopic CNV

Bayer’s Eylea approved in Japan for myopic CNV

22-09-2014

Bayer Yakuhin, the Japanese health care subsidiary if Germany’s Bayer has received approval from Japan’s…

BayerEyleaJapanOphthalmicsPharmaceuticalRegeneron PharmaceuticalsRegulation

Bayer plans to focus entirely on Life Science businesses

Bayer plans to focus entirely on Life Science businesses

18-09-2014

The board of management of Germany’s Bayer AG plans to focus the Bayer Group entirely on the Life Science…

BayerFinancialGermanyManagementPharmaceutical

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

02-09-2014

German pharma and chemical major Bayer has released results from the X-VeRT* study, demonstrating that…

BayerCardio-vascularPharmaceuticalResearchXarelto

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

11-08-2014

The treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through…

BayerGleevecGlivecMarkets & MarketingNovartisOncologyPfizerPharmaceuticalStivargaSutent

Eylea approved for diabetic macular edema in Europe

Eylea approved for diabetic macular edema in Europe

11-08-2014

The European Commission has approved German pharma major Bayer’s Eylea (aflibercept) injection for…

BayerEuropeEyleaOphthalmicsOphthalmologyPharmaceuticalRegeneronRegulation

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

30-07-2014

Germany’s pharma and life sciences major Bayer posted a solid set of second-quarter 2014 financial…

BayerCancerConsumer HealthFinancialGermanyGermanyPharmaceuticalPulmonary hypertension

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Bayer the latest in anticoagulant lawsuit action

Bayer the latest in anticoagulant lawsuit action

16-07-2014

German drug major Bayer is just one of the latest companies to be facing lawsuits over its anticoagulants,…

BayerBoehringer IngelheimHematologyHematologyLegalPharmaceuticalPradaxaRivaroxabanUSAWarfarin SodiumXarelto

Malini Moorthy joins Bayer as head of litigation

Malini Moorthy joins Bayer as head of litigation

16-07-2014

Bayer Corporation, a US subsidiary of German drug major Bayer has hired Malini Moorthy as head of its…

BayerBayer CorporationBoardroomEconomy of GermanyGermanyHead of the litigation departmentIG FarbenMalini MoorthyPharmaceuticalUSA

Bayer milestone for Compugen in cancer immunotherapy deal

Bayer milestone for Compugen in cancer immunotherapy deal

07-07-2014

Shares of Israel-based Compugen rose nearly 4% in pre-market trading today, after it said it has achieved…

BayerCompugenFinancialOncologyPharmaceuticalResearch

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

20-06-2014

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved German pharma major Bayer’s oral…

BayerJapanNexavarOncologyPharmaceuticalRegulation

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

11-06-2014

German pharma major Bayer has submitted an application to the European Medicines Agency seeking marketing…

BayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulation

1 to 25 of 290 results

Parexel

Parexel

Back to top